A multicenter, multicohort, phase II study of trastuzumab deruxtecan (DS-8201a) in subjects with HER2-expressing metastatic colorectal cancer - Yoshino, T.; Siena, S.; Dalal, R.; Okuda, Y.; Yamamoto, E.; Grothey, A. (Annals of oncology, 2018)